These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 8393912)

  • 1. Identification of a fifth neutralizable site on type O foot-and-mouth disease virus following characterization of single and quintuple monoclonal antibody escape mutants.
    Crowther JR; Farias S; Carpenter WC; Samuel AR
    J Gen Virol; 1993 Aug; 74 ( Pt 8)():1547-53. PubMed ID: 8393912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Escape mutants of foot-and-mouth disease virus selected by monoclonal antibodies directed to a trypsin-sensitive neutralization epitope.
    Das BR; Pattnaik B; Venkataramanan R; Rai DV
    Acta Virol; 1997 Jun; 41(3):131-8. PubMed ID: 9385400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutralization of foot-and-mouth disease virus can be mediated through any of at least three separate antigenic sites.
    Xie QC; McCahon D; Crowther JR; Belsham GJ; McCullough KC
    J Gen Virol; 1987 Jun; 68 ( Pt 6)():1637-47. PubMed ID: 2438378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence for at least four antigenic sites on type O foot-and-mouth disease virus involved in neutralization; identification by single and multiple site monoclonal antibody-resistant mutants.
    McCahon D; Crowther JR; Belsham GJ; Kitson JD; Duchesne M; Have P; Meloen RH; Morgan DO; De Simone F
    J Gen Virol; 1989 Mar; 70 ( Pt 3)():639-45. PubMed ID: 2471793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutralizing epitopes of type O foot-and-mouth disease virus. II. Mapping three conformational sites with synthetic peptide reagents.
    Parry NR; Barnett PV; Ouldridge EJ; Rowlands DJ; Brown F
    J Gen Virol; 1989 Jun; 70 ( Pt 6)():1493-503. PubMed ID: 2471812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antigenic features of foot-and-mouth disease virus serotype Asia1 as revealed by monoclonal antibodies and neutralization-escape mutants.
    Sanyal A; Venkataramanan R; Pattnaik B
    Virus Res; 1997 Aug; 50(2):107-17. PubMed ID: 9282776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of monoclonal antibodies against a type SAT 2 foot-and-mouth disease virus.
    Crowther JR; Rowe CA; Butcher R
    Epidemiol Infect; 1993 Oct; 111(2):391-406. PubMed ID: 7691630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal antibodies to an Indian strain of type A foot-and-mouth disease virus.
    Tosh C; Venkataramanan R; Pattnaik B; Hemadri D; Sanyal A
    Acta Virol; 1999 Aug; 43(4):219-25. PubMed ID: 10749367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epitope mapping of foot-and-mouth disease virus with neutralizing monoclonal antibodies.
    Bolwell C; Clarke BE; Parry NR; Ouldridge EJ; Brown F; Rowlands DJ
    J Gen Virol; 1989 Jan; 70 ( Pt 1)():59-68. PubMed ID: 2471783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutralizing epitopes of type O foot-and-mouth disease virus. I. Identification and characterization of three functionally independent, conformational sites.
    Barnett PV; Ouldridge EJ; Rowlands DJ; Brown F; Parry NR
    J Gen Virol; 1989 Jun; 70 ( Pt 6)():1483-91. PubMed ID: 2471811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of a subtype-specific neutralization epitope in foot-and-mouth disease virus of a different subtype.
    Hernández J; Martínez MA; Rocha E; Domingo E; Mateu MG
    J Gen Virol; 1992 Jan; 73 ( Pt 1)():213-6. PubMed ID: 1370534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal antibodies, against O1 serotype foot-and-mouth disease virus, from a natural bovine host, recognize similar antigenic features to those defined by the mouse.
    Barnett PV; Samuel AR; Pullen L; Ansell D; Butcher RN; Parkhouse RM
    J Gen Virol; 1998 Jul; 79 ( Pt 7)():1687-97. PubMed ID: 9680132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Host cell selection of antigenic variants of foot-and-mouth disease virus.
    Bolwell C; Brown AL; Barnett PV; Campbell RO; Clarke BE; Parry NR; Ouldridge EJ; Brown F; Rowlands DJ
    J Gen Virol; 1989 Jan; 70 ( Pt 1)():45-57. PubMed ID: 2471782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of foot-and-mouth disease virus type O1 Brugge neutralization epitopes using monoclonal antibodies.
    Stave JW; Card JL; Morgan DO
    J Gen Virol; 1986 Oct; 67 ( Pt 10)():2083-92. PubMed ID: 2428926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of neutralizing antigenic sites on the surface of type A12 foot-and-mouth disease virus.
    Baxt B; Vakharia V; Moore DM; Franke AJ; Morgan DO
    J Virol; 1989 May; 63(5):2143-51. PubMed ID: 2467993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antigenicity and immunogenicity of synthetic peptides of foot-and-mouth disease virus.
    Meloen RH; Puyk WC; Meijer DJ; Lankhof H; Posthumus WP; Schaaper WM
    J Gen Virol; 1987 Feb; 68 ( Pt 2)():305-14. PubMed ID: 2434606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antigenic sites on foot-and-mouth disease virus type A10.
    Thomas AA; Woortmeijer RJ; Puijk W; Barteling SJ
    J Virol; 1988 Aug; 62(8):2782-9. PubMed ID: 2455819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural and serological evidence for a novel mechanism of antigenic variation in foot-and-mouth disease virus.
    Parry N; Fox G; Rowlands D; Brown F; Fry E; Acharya R; Logan D; Stuart D
    Nature; 1990 Oct; 347(6293):569-72. PubMed ID: 1699132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralization sites of type O1 foot-and-mouth disease virus defined by monoclonal antibodies and neutralization-escape virus variants.
    Stave JW; Card JL; Morgan DO; Vakharia VN
    Virology; 1988 Jan; 162(1):21-9. PubMed ID: 2827379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of a foot-and-mouth disease virus immunodominant epitope by a filamentous bacteriophage vector.
    Kim YJ; Lebreton F; Kaiser C; Crucière C; Rémond M
    Arch Virol; 2004 Feb; 149(2):365-77. PubMed ID: 14745601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.